CSB Bancorp Q2 2026 10-Q: Nonperforming Loans Jump to $7.3M, Allowance Builds
CSBB has more than doubled off its 52-week low of $36 on elevated volume (2.6× avg).
Summary
CSB Bancorp's Q2 2026 10-Q shows nonperforming loans jumped to $7.3 million from $652 thousand at year-end, prompting a higher allowance for credit losses. The bank remains well-capitalized with strong liquidity.
Key Events · Earnings and Guidance · CSBB
-
Nonperforming Loans Surge
Nonperforming loans increased to $7.3 million (0.84% of total loans) at June 30, 2026, from $652 thousand (0.08%) at December 31, 2025. $6.7 million in loans were placed on nonaccrual status during the first half of 2026.
-
Allowance for Credit Losses Increased
The allowance for credit losses rose to $13.5 million (1.56% of total loans) from $12.5 million (1.50%) at year-end. Coverage of nonperforming loans fell to 1.9x from 19.1x, reflecting the sharp increase in problem loans.
-
Credit Quality Deterioration
Substandard loans totaled $60.2 million at June 30, 2026, up from $60.6 million at year-end. One individually evaluated loan relationship and increased home equity line risk drove the higher provision.
-
Capital and Liquidity Remain Strong
Total risk-based capital ratio was 16.8%, Tier 1 leverage ratio 10.4%, and tangible common equity to tangible assets 9.9%. Liquidity sources totaled $351.7 million with a liquidity ratio of 30.5%, well above the 20% minimum.
Analysis · CSBB · Finance
The full 10-Q reveals a significant deterioration in credit quality that was not apparent in the earlier earnings release. Nonperforming loans surged to $7.3 million, or 0.84% of total loans, up from just $652 thousand at year-end 2025. The allowance for credit losses was increased to $13.5 million, though coverage of nonperforming loans fell to 1.9x from 19.1x at year-end. The bank remains well-capitalized with strong liquidity, but the sharp rise in problem loans warrants attention.
At the time of this filing, CSBB was trading at $74.31 on OTC in the Finance sector, with a market capitalization of approximately $195.2M. The 52-week trading range was $36.00 to $74.87. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.